{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:41:15Z","timestamp":1765888875614,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00296-022-05129-w","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T09:04:24Z","timestamp":1650099864000},"page":"1113-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TNF\u03b1 inhibitor biosimilars associated with alopecia areata. Case-based review"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":false,"given":"E.","family":"Pelechas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":false,"given":"P. V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"A. A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"5129_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","volume":"49","author":"M Fukuyama","year":"2022","unstructured":"Fukuyama M, Ito T, Ohyama M (2022) Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 49:19\u201336","journal-title":"J Dermatol"},{"key":"5129_CR2","first-page":"579","volume":"35","author":"PP Sfikakis","year":"2017","unstructured":"Sfikakis PP, Bournia VK, Sidiropoulos P et al (2017) Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 35:579\u2013585","journal-title":"Clin Exp Rheumatol"},{"key":"5129_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV et al (2014) Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43:447\u2013457","journal-title":"Semin Arthritis Rheum"},{"key":"5129_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"M Her","year":"2016","unstructured":"Her M, Kavanaugh A (2016) Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137:19\u201327","journal-title":"J Allergy Clin Immunol"},{"key":"5129_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","volume":"10","author":"O Boyman","year":"2014","unstructured":"Boyman O, Comte D, Spertini F (2014) Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 10:612\u2013627","journal-title":"Nat Rev Rheumatol"},{"key":"5129_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.31138\/mjr.32.2.96","volume":"32","author":"AA Drosos","year":"2021","unstructured":"Drosos AA, Pelechas E, Kaltsonoudis E et al (2021) Biologic therapies and autoimmune phenomena. Mediterr J Rheumatol 32:96\u2013103","journal-title":"Mediterr J Rheumatol"},{"key":"5129_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242\u2013251","journal-title":"Medicine (Baltimore)"},{"key":"5129_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/03009740902922612","volume":"38","author":"SA Exarchou","year":"2009","unstructured":"Exarchou SA, Voulgari PV, Markatseli TE et al (2009) Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 38:328\u2013331","journal-title":"Scand J Rheumatol"},{"key":"5129_CR9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A et al (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513\u20132518","journal-title":"Arthritis Rheum"},{"key":"5129_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","volume":"67","author":"PV Voulgari","year":"2008","unstructured":"Voulgari PV, Markatseli TE, Exarchou SA et al (2008) Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 67:567\u2013570","journal-title":"Ann Rheum Dis"},{"key":"5129_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000511985","volume":"13","author":"E Masukawa","year":"2021","unstructured":"Masukawa E, Matsushima Y, Habe K et al (2021) Two cases of cutaneous adverse effects induced by tumor necrosis factor-alpha inhibitors. Case Rep Dermatol 13:238\u2013243","journal-title":"Case Rep Dermatol"},{"key":"5129_CR12","first-page":"596","volume":"33","author":"R Youssef","year":"2020","unstructured":"Youssef R, Saad S, Hendrick S (2020) Alopecia universalis and onychodystrophy during treatment with adalimumab. Proc (Bayl Univ Med Cent) 33:596\u2013597","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"5129_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00393-018-0464-z","volume":"77","author":"P Ostojic","year":"2018","unstructured":"Ostojic P, Pavlov-Dolijanovic S (2018) Alopecia universalis in a patient with rheumatoid arthritis developed during treatment with adalimumab. Z Rheumatol 77:412\u2013415","journal-title":"Z Rheumatol"},{"key":"5129_CR14","doi-asserted-by":"publisher","DOI":"10.5070\/D3237035733","author":"G Mel\u00e9-Ninot","year":"2017","unstructured":"Mel\u00e9-Ninot G, Exp\u00f3sito-Serrano V, Quintana Codina M et al (2017) Adalimumab-related alopecia in a patient affected by psoriasis. Dermatol Online J. https:\/\/doi.org\/10.5070\/D3237035733","journal-title":"Dermatol Online J"},{"key":"5129_CR15","doi-asserted-by":"publisher","DOI":"10.5070\/D3233034290","author":"LN Craddock","year":"2017","unstructured":"Craddock LN, Cooley DM, Endo JO et al (2017) TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renb\u00f6k mold. Dermatol Online J. https:\/\/doi.org\/10.5070\/D3233034290","journal-title":"Dermatol Online J"},{"key":"5129_CR16","doi-asserted-by":"publisher","DOI":"10.5070\/D32111029286","author":"H Toda-Brito","year":"2015","unstructured":"Toda-Brito H, Lopes L, Soares-Almeida L et al (2015) Adalimumab-induced psoriatic alopecia\/alopecia areata-like reaction in a patient with Crohn\u2019s disease. Dermatol Online J. https:\/\/doi.org\/10.5070\/D32111029286","journal-title":"Dermatol Online J"},{"key":"5129_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1590\/abd1806-4841.20153084","volume":"90","author":"LB Ribeiro","year":"2015","unstructured":"Ribeiro LB, Rego JC, Estrada BD et al (2015) Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol 90:232\u2013235","journal-title":"An Bras Dermatol"},{"key":"5129_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5070\/D331C9H7FX","volume":"16","author":"E Beccastrini","year":"2010","unstructured":"Beccastrini E, Squatrito D, Emmi G et al (2010) Alopecia areata universalis during off-label treatment with infliximab in a patient with Beh\u00e7et disease. Dermatol Online J 16:15","journal-title":"Dermatol Online J"},{"key":"5129_CR19","first-page":"892","volume":"27","author":"MV Hern\u00e1ndez","year":"2009","unstructured":"Hern\u00e1ndez MV, Nogu\u00e9s S, Ruiz-Esquide V et al (2009) Development of alopecia areata after biological therapy with TNF-alpha Blockers: description of a case and review of the literature. Clin Exp Rheumatol 27:892\u2013893","journal-title":"Clin Exp Rheumatol"},{"key":"5129_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2310\/7750.2008.07095","volume":"13","author":"C Kirshen","year":"2009","unstructured":"Kirshen C, Kanigsberg N (2009) Alopecia areata following adalimumab. J Cutan Med Surg 13:48\u201350","journal-title":"J Cutan Med Surg"},{"key":"5129_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/09273940802596559","volume":"17","author":"Y Pan","year":"2009","unstructured":"Pan Y, Rao NA (2009) Alopecia areata during etanercept therapy. Ocul Immunol Inflamm 17:127\u2013129","journal-title":"Ocul Immunol Inflamm"},{"key":"5129_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000162180","volume":"217","author":"Y Chaves","year":"2008","unstructured":"Chaves Y, Duarte G, Ben-Said B et al (2008) Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217:380","journal-title":"Dermatology"},{"key":"5129_CR23","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/archderm.142.12.1654","volume":"142","author":"N Garcia Bartels","year":"2006","unstructured":"Garcia Bartels N, Lee HH, Worm M et al (2006) Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 142:1654\u20131655","journal-title":"Arch Dermatol"},{"key":"5129_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","volume":"25","author":"M Ferran","year":"2011","unstructured":"Ferran M, Calvet J, Almirall M et al (2011) Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-\u03b1 blocker agents: report of five cases and review of the literature. J Eur Acad Dermatol Venereol 25:479\u2013484","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5129_CR25","first-page":"534","volume":"11","author":"KM Alghamdi","year":"2012","unstructured":"Alghamdi KM, Khurrum H, Taieb A et al (2012) Treatment of generalized vitiligo with anti-TNF-\u03b1 agents. J Drugs Dermatol 11:534\u2013539","journal-title":"J Drugs Dermatol"},{"key":"5129_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1573397116666201119151349","volume":"17","author":"E Pelechas","year":"2021","unstructured":"Pelechas E, Papoudou-Bai A, Voulgari PV et al (2021) Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Curr Rheumatol Rev 17:267\u2013270","journal-title":"Curr Rheumatol Rev"},{"key":"5129_CR27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H et al (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"key":"5129_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 78:1\u201312","journal-title":"J Am Acad Dermatol"},{"key":"5129_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R et al (2018) Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichol 10:51\u201360","journal-title":"Int J Trichol"},{"key":"5129_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000291","volume":"5","author":"JSS Concha","year":"2018","unstructured":"Concha JSS, Werth VP (2018) Alopecias in lupus erythematosus. Lupus Sci Med 5:e000291","journal-title":"Lupus Sci Med"},{"key":"5129_CR31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.16808","volume":"179","author":"F Rajabi","year":"2018","unstructured":"Rajabi F, Drake LA, Senna MM et al (2018) Alopecia areata: a review of disease pathogenesis. Br J Dermatol 179:1033\u20131048","journal-title":"Br J Dermatol"},{"key":"5129_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043\u20131049","journal-title":"Nat Med"},{"key":"5129_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jdv.14775","volume":"32","author":"SH Loh","year":"2018","unstructured":"Loh SH, Moon HN, Lew BL et al (2018) Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients. J Eur Acad Dermatol Venereol 32:1028\u20131033","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5129_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jamadermatol.2014.1544","volume":"150","author":"L Gorcey","year":"2014","unstructured":"Gorcey L, Gordon Spratt EA, Leger MC (2014) Alopecia universalis successfully treated with adalimumab. JAMA Dermatol 150:1341\u20131344","journal-title":"JAMA Dermatol"},{"key":"5129_CR35","first-page":"450","volume":"11","author":"C Zschoche","year":"2013","unstructured":"Zschoche C, Bidier M, Hadaschik E (2013) Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible. J Dtsch Dermatol Ges 11:450\u2013453","journal-title":"J Dtsch Dermatol Ges"},{"key":"5129_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annder.2011.01.047","volume":"138","author":"E Le Bidre","year":"2011","unstructured":"Le Bidre E, Chaby G, Martin L et al (2011) Alopecia areata during anti-TNF alpha therapy: nine cases. Ann Dermatol Venereol 138:285\u2013293","journal-title":"Ann Dermatol Venereol"},{"key":"5129_CR37","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jaad.2014.03.005","volume":"70","author":"M Tauber","year":"2014","unstructured":"Tauber M, Buche S, Reygagne P et al (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70:1146\u20131149","journal-title":"J Am Acad Dermatol"},{"key":"5129_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","volume":"138","author":"JM Bae","year":"2018","unstructured":"Bae JM, Kim M, Lee HH et al (2018) Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Invest Dermatol 138:768\u2013774","journal-title":"J Invest Dermatol"},{"key":"5129_CR39","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L et al (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102:3372\u20133377","journal-title":"Proc Natl Acad Sci USA"},{"key":"5129_CR40","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"LC Silva","year":"2010","unstructured":"Silva LC, Ortigosa LC, Benard G (2010) Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2:817\u2013833","journal-title":"Immunotherapy"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05129-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05129-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05129-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T07:03:21Z","timestamp":1653203001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05129-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5129"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05129-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (E. Pelechas, PV. Voulgari & AA. Drosos) declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As per our institution\u2019s ethic\u2019s approval, when there is no sensitive data of the patient presented (face characteristics, name\/surname\/date of birth on photos\/x-rays\/ct\/mri etc.) there is no need for a specific approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}